Applications of artificial intelligence in the analysis of histopathology images of gliomas: a review

Overview

• The paper examines 83 publicly available research studies that have proposed AI-based methods for analyzing whole-slide histopathology images of human gliomas.
• The diagnostic tasks covered include glioma subtyping, grading, molecular marker prediction, and survival prediction.
• The research focuses primarily on the assessment of hematoxylin and eosin-stained tissue sections of adult-type diffuse gliomas.
• The majority of studies (52/83) are based on the publicly available glioblastoma and low-grade glioma datasets from The Cancer Genome Atlas (TCGA).

Plain English Explanation

Gliomas are a type of brain tumor, and diagnosing them has become increasingly complex in recent years. Researchers are exploring the use of artificial intelligence (AI)-based methods to assist with glioma diagnosis and prognosis prediction by analyzing histopathology images of the tumor tissue.

This review examines 83 different research studies that have proposed AI-based approaches for analyzing whole-slide histopathology images of human gliomas. The researchers looked at studies covering a range of diagnostic tasks, including:

• Subtyping: Determining the specific type of glioma
• Grading: Assessing the aggressiveness of the tumor
• Molecular marker prediction: Identifying the presence of certain genetic markers
• Survival prediction: Estimating a patient's likely outcome

The majority of these studies focused on analyzing hematoxylin and eosin-stained tissue sections, which are a common way of preparing and staining tumor samples for microscopic examination. Most of the studies (52/83) used publicly available datasets from The Cancer Genome Atlas (TCGA), which contains information on glioblastoma and low-grade gliomas.

The researchers found that the most common AI-based approach used in these studies was convolutional neural networks, a type of deep learning algorithm that is well-suited for analyzing visual data like histopathology images. Many of the studies also incorporated clinical data, genetic data, or magnetic resonance imaging (MRI) scans to improve the accuracy of their AI models.

Overall, the AI-based methods have shown promising results, but they have not yet been widely adopted for routine use in clinical settings. The researchers emphasize the need for further validation of these techniques on larger, more diverse datasets with high-quality clinical and molecular pathology annotations to demonstrate their real-world applicability.

Technical Explanation

The review examines 83 publicly available research studies that have proposed AI-based methods for analyzing whole-slide histopathology images of human gliomas. The studies cover a range of diagnostic tasks, including glioma subtyping (23/83), grading (27/83), molecular marker prediction (20/83), and survival prediction (29/83).

The majority of the studies (52/83) are based on the publicly available glioblastoma and low-grade glioma datasets from The Cancer Genome Atlas (TCGA), while a smaller number of studies employed other datasets in isolation (16/83) or in addition to the TCGA datasets (15/83). This focus on the TCGA datasets suggests a need for more diverse data sources to be explored.

In terms of methodological approaches, the most commonly used AI techniques were convolutional neural networks (63/83), which are well-suited for analyzing visual data like histopathology images. Many of the studies also incorporated clinical data, omics data, or magnetic resonance imaging (MRI) scans to enhance the performance of their AI models.

The researchers note that the majority of the studies (35/83) analyzed tissue samples at 20x magnification, which is a common level of detail used in histopathology. However, some studies have explored the use of higher resolutions or even full-resolution images to capture more detailed features.

Overall, the review highlights the growing body of research on AI-based methods for glioma diagnosis and prognosis prediction. While the results have been promising, the researchers emphasize the need for further validation on larger, multi-site datasets with high-quality clinical and molecular pathology annotations to demonstrate the routine applicability of these techniques in real-world clinical settings.

Critical Analysis

The review provides a comprehensive overview of the current state of research on AI-based methods for glioma diagnosis and prognosis prediction. The researchers have done a thorough job of surveying the existing literature and summarizing the key methodological aspects and findings.

One notable limitation is the heavy reliance on the TCGA datasets, which may not be representative of the full diversity of glioma cases encountered in clinical practice. The researchers acknowledge this and call for the use of additional, more diverse datasets to validate the AI-based methods.

Another area for potential improvement is the integration of clinical data, omics data, and imaging data in a more systematic and standardized way. While many studies have explored the incorporation of these additional data sources, a more consistent approach could lead to more robust and generalizable AI models.

Additionally, the review does not delve into the interpretability and explainability of the AI-based methods. As these techniques are intended to support clinical decision-making, it will be important for future research to address the need for transparent and understandable models that can provide insights into the factors driving their predictions.

Overall, this review provides a valuable summary of the current state of the art in AI-based glioma diagnosis and prognosis prediction. The researchers have identified several important directions for future research, which will be crucial for demonstrating the real-world applicability of these techniques and facilitating their adoption in clinical practice.

Conclusion

This comprehensive review examines the current state of research on the use of AI-based methods for analyzing whole-slide histopathology images of human gliomas. The researchers found that the focus of this field is on the assessment of hematoxylin and eosin-stained tissue sections, with a particular emphasis on the publicly available TCGA datasets.

The most common AI-based approaches utilized in these studies are convolutional neural networks, which have shown promising results for tasks such as glioma subtyping, grading, molecular marker prediction, and survival prediction. Many studies have also incorporated additional data sources, such as clinical information, omics data, and imaging scans, to enhance the performance of their AI models.

While the AI-based methods have demonstrated their potential, the researchers emphasize the need for further validation on larger, more diverse datasets with high-quality clinical and molecular pathology annotations. Addressing issues of interpretability and explainability will also be crucial for facilitating the adoption of these techniques in real-world clinical settings.

Overall, this review highlights the significant progress that has been made in the field of AI-assisted glioma diagnosis and prognosis prediction, while also identifying important areas for future research and development to drive the clinical translation of these promising techniques.